TAT 2017
 
Monday, March 6, 2017
09:00 - 10:15Plenary Session 1: Opening Ceremony [More Info]
Chair: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
09:00 - 09:07Opening Address on behalf of Gustave Roussy [More Info]
Alexander Eggermont, Institut Gustave Roussy, Villejuif, France
09:07 - 09:15Opening Address on behalf of TAT 2017 Organizing Committee [More Info]
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
09:15 - 09:45O1.1 TAT 2017 Honorary Award Invited Lecture: Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms [More Info]
Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY, USA
09:45 - 10:15O1.2 Keynote Lecture: Positioning Immune checkpoint blockade within the systemic anti-cancer armamentarium [More Info]
Alexander Eggermont, Institut Gustave Roussy, Villejuif, France


10:15 - 10:40Break [More Info]


10:40 - 12:20Plenary Session 2: Immuno-oncology (1): Novel combinations, novel approaches [More Info]
Chair: Alexander Eggermont, Institut Gustave Roussy, Villejuif, France
Chair: Aurélien Marabelle, Institut Gustave Roussy, Villejuif, France
10:40 - 11:00O2.1 Customizing cancer immunotherapies to match the intrinsic tumor microenvironment [More Info]
Brad Nelson, British Columbia Cancer Agency, Vancouver, Canada
11:00 - 11:20O2.2 Combining IO with IO: rationale and clinical perspectives [More Info]
Ignacio Melero, University of Navarra, Navarra, Spain
11:20 - 11:40O2.3 Clinical stage: Immune Design (TLR-4 agonist) [More Info]
Carlos Paya, Immune Design, South San Francisco, CA, USA
11:40 - 12:00O2.4 Turning Tumor Mutations into Personalized Cancer Therapies [More Info]
Roman Yelensky, Gritstone Oncology, Cambridge, MA, USA
12:00 - 12:20General discussion


12:20 - 13:35Lunch & Poster Viewing


13:35 - 13:45Welcome address on behalf of ESMO [More Info]
Josep Tabernero, VHIO/Vall d’Hebron University Hospital, Barcelona, Spain
13:45 - 15:15Plenary Session 3: Phase 1 Studies - Completed or in progress (miscellaneous drugs & targets) [More Info]
Chair: Lesley Seymour, Canadian Cancer Trials Group, Kingston, Canada
Chair: Udai Banerji, The Institute of Cancer Research and The Royal Marsden, London, UK
13:45 - 14:00O3.1 A Phase 1/1b, first-in-human study of IPI-549, a PI3K-? inhibitor and myeloid targeting agent, as monotherapy and in combination with nivolumab in patients with advanced solid tumors [More Info]
Anthony Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA
14:00 - 14:15O3.2 TAX-TORC: investigator initiated phase I trial of vistusertib (AZD2014), a dual m-TORC1/2 inhibitor, in combination with weekly paclitaxel [More Info]
Udai Banerji, The Institute of Cancer Research and The Royal Marsden, London, UK
14:15 - 14:30O3.3. Phase I/II Study of AC0010 in Patients with EGFR T790M Mutant Non-Small Cell Lung Cancer (NSCLC) [More Info]
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General hospital, Guangzhou, China
14:30 - 14:45O3.4 Phase IB study of CC-122 and obinutuzumab in relapsed or refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma [More Info]
Jean-Marie Michot, Institut Gustave Roussy, Villejuif, France
14:45 - 15:00O3.5 Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations. [More Info]
Alan Ho, Memorial Sloan Kettering Cancer Center, New York, NY, USA
15:00 - 15:15O3.6 Model-based dose escalation of phase I trials in Japanese patients. Could it be more efficient than rule-based designs? [More Info]
Akihiko Shimomura, National Cancer Center Hospital, Tokyo, Japan


15:15 - 15:45Break [More Info]


15:45 - 17:25Plenary Session 4: Early-phase drug development in hematology [More Info]
Chair: Vincent Ribrag, Institut Gustave Roussy, Villejuif, France
15:45 - 16:05O4.1 Targeting epigenetics in hematological malignancies [More Info]
Scott Ribich, Epizyme, Cambridge, MA, USA
16:05 - 16:25O4.2 CAR T-cells, do we need new modified CAR T-cell designs? [More Info]
Loan Hoang-Sayag, Cellectis, Paris, France
16:25 - 16:45O4.3 Targeting RNA splicing in cancer [More Info]
Peter Smith, H3 Biomedicine, Arlington, MA, USA
16:45 - 17:05O4.4 BiTEs: what are the next steps? [More Info]
Ralf Bargou, Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany
17:05 - 17:25General discussion


17:25 - 17:45Poster Awarding Ceremony [More Info]
Chair: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
Chair: Giuseppe Giaccone, Georgetown University, Washington, DC, USA
17:25 - 17:30Introduction Poster Awards
17:30 - 17:37P4.2 Potentiation of targeted breast cancer therapy through CDK8/19 inhibition [More Info]
Eugenia Broude, University of South Carolina, Columbia, SC, United States
17:37 - 17:45P7.4 Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO3 fusions [More Info]
Erica Torchiaro, Candiolo Cancer Institute – FPO IRCCS, Turin, Italy


17:45 - 19:00Poster Viewing & Reception [More Info]